Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.30 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA2 | P00918 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949492 | 1.00 | TSHR (0.51) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL24279756 | 0.83 | TSHR (0.49) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL19370334 | 0.83 | TSHR (0.49) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL27056828 | 0.83 | TSHR (0.49) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL11948326 | 0.82 | TSHR (0.47) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL11949482 | 0.82 | TSHR (0.47) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL17879657 | 0.78 | TSHR (0.37) | TSHRCA9CA12CA1CA2 | |
| SCHEMBL14477769 | 0.77 | TSHR (0.46) | TSHRNR3C1FYNADRA2AADORA3 | |
| SCHEMBL14565314 | 0.75 | — | — | |
| SCHEMBL12450451 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142296-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL)-5-METHOXYTETRAHYDROFURAN-3-OL AND ACETYLATED DERIVATIVES THEREOF, FREE OF PYRANOSE COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2014-05-22 | — | — | US | disclosed |
| US-8637649-B2 | Process for the preparation of (2R,3S)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3-OL and acetylated derivatives thereof, free of pyranose compounds | JOHNSON MATTHEY PUBLIC LIMITED CO. (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20120238734-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL)-5-METHOXYTETRAHYDROFURAN-3-OL AND ACETYLATED DERIVATIVES THEREOF, FREE OF PYRANOSE COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142296-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL)-5-METHOXYTETRAHYDROFURAN-3-OL AND ACETYLATED DERIVATIVES THEREOF, FREE OF PYRANOSE COMPOUNDS | DERA, MPG, TYMS | TSHR 4169/4885NR3C1 695/4885FYN 3556/4885 |
| US-20120238734-A1 | PROCESS FOR THE PREPARATION OF (2R,3S)-2-(HYDROXYMETHYL)-5-METHOXYTETRAHYDROFURAN-3-OL AND ACETYLATED DERIVATIVES THEREOF, FREE OF PYRANOSE COMPOUNDS | MRM1, DPYD, POP1 | TSHR 3581/4885NR3C1 1934/4885FYN 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.